Tetra Bio Pharma Inc (TBPMQ)

[12yearplan]

Tetra Biopharma Inc. Tetra Bio Pharma is a publicly traded company (CSE:TBP & OTC GRPOF) engaged in cannabis derived drug discovery with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation, clinical and safety data required for inclusion into the existing bio-pharma industry by regulators physicians and insurance companies. According to Canadian and USA drug regulatory agencies, there is no evidence to support the safety and efficacy of marijuana for use inthe treatment of pain or any other indication. We have a number of programs at various stages of development ranging from Pre-Clinical all the way through to Phase III. We are interested in establishing partnerships and alliances with companies that have an interest in pain management, cancer, inflammation, PTSD, and other neurological conditions Summary of Products PPP001 - Alternative delivery mechanism of smokeable cannabis for treating late stage cancer pain commencing Phase III end of Q4 2017; PPP002 - Dronabinol XL, mucoadhesive tablet for treating chemo induced nausea and vomiting as well as chronic pain with excellent potential for opioid sparing; Phase II commencing end of Q4 2017; PPP003 - Eye drop for treating ocular inflammation and eye pain and dry eye (pre-clinical); PPP004- Topical cream for treating neuropathic pain (pre-Clinical) sychiatric and neurological conditions.
https://bif17.eventsbio.com/connect/search.ww#loadSearch-searchPhrase=tetra&searchType=session&tc=0&sortBy=titleSort&p=&i(11353)=&i(11356)=&i(11366)=&i(11345)=